Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “DIURESIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources

Blood volume following diuresis induced by furosemide.

Changes in blood volume were investigated following intravenous injection of a single dose of furosemide in 21 patients with pulmonary edema. In a subset of 10 patients in whom the blood urea nitrogen level was 11.4 +/- 2.2 mg/dl and the serum creatinine level was 1.3 +/- 0.1 mg/dl and in whom total urine output exceeded 1 liter over a four- to six-hour interval ("diuretic" group), no significant change in plasma or total blood volume was observed, nor were there any significant changes in hematocrit. In a "nondiuretic" group of 11 patients who had moderately decreased renal function (blood urea nitrogen level 59.3 +/- 13.0 mg/dl and serum creatinine level 2.3 +/- 0.3 mg/dl) and in whom total urine output was less than 1 liter over the four- to six-hour interval, there was a significant increase in blood volume with a concomitant decrease in hematocrit and hemoglobin levels. Furosemide-induced diuresis therefore did not deplete intravascular volume. To the contrary, actions of furosemide that were independent of its diuretic action were associated with an expansion of plasma volume in the absence of diuresis. This may be related to the venous capacitance effects of furosemide with lowering of venous resistance and, therefore, lowering of the capillary hydrostatic pressure. In addition, there was an increase in colloid osmotic pressure. Both mechanisms increase the effective oncotic pressure gradient, which favors reabsorption of extravascular (edema) fluid. It is concluded that intravascular volume was therefore replenished at a rate equal to or in excess of the volume removed by diuresis.

Adult↗

Diuresis with continuous infusion of furosemide after cardiac surgery.

We prospectively evaluated the diuretic effect of furosemide administered by bolus injection and by continuous infusion in 18 cardiac surgery patients. Nine patients were randomly assigned to receive 0.3 mg/kg of furosemide as a bolus injection at time 0 and again 6 hours later (nine patients) or 0.05 mg/kg per hour of furosemide as a constant infusion for 12 hours (nine patients). There were no significant differences between groups with respect to age, weight, creatinine clearance, changes in serum sodium and potassium levels, total urinary concentrations of sodium and potassium, or total urine volume for 12 hours. Diuresis during continuous infusion of furosemide was less variable from hour to hour than after bolus injection of furosemide and was sustained throughout the infusion period. Although the continuous infusion of furosemide will not provide the rapid and vigorous diuresis that is necessary in some clinical situations, it may be useful whenever a gentle, sustained diuresis is desired.

Cardiac Surgical Procedures↗

Clonidine-induced increase of renal prostaglandin activity and water diuresis in conscious dogs.

I.v. administration of clonidine to conscious dogs induces a water diuresis with hyposmotic urine and minor effect on electrolyte excretion. The diuresis is preceded by an increased urinary PGE excretion, but no change of urinary ADH output is observed. Plasma renin activity decreases. Both ADH infusion and indomethacin pretreatment inhibit the diuretic effect of clonidine. The results support the hypothesis that clonidine-induced water diuresis is mediated via an anti ADH effect due to increased renal prostaglandin activity. Moreover the results suggest that there is no direct stimulation of renin release by PGE.

Animals↗

Taurine-induced diuresis and natriuresis in cirrhotic patients with ascites.

Taurine is a non-protein sulfur amino acid widely distributed in mammalian tissues, with poorly understood functions. Taurine administration has a variety of hemodynamic effects, including improvement of cardiac function and suppression of sympathetic activity. Increased urinary volume and sodium excretion have been reported in taurine-fed hamsters. Since patients with ascitic liver cirrhosis have severe hemodynamic and renal abnormalities potentially sensitive to taurine feeding, we evaluated the effects of the i.v. infusion of taurine on urinary flow and sodium excretion and on the hormones involved in the control of hydrosaline homeostasis. Eight cirrhotic patients with tense ascites were given an i.v. bolus of taurine (16 mumoles in 40 ml of saline). The next day patients were given saline only, as a control. Diuresis, urinary sodium and plasma renin activity, aldosterone, atrial natriuretic peptide and arginine vasopressin were measured for the following 6 hrs. Plasma taurine increased ten fold after infusion, then decreased exponentially. No side effects were recorded. After taurine, but not after saline, there was a prompt and significant increase in both urinary volume and sodium excretion. Diuresis increased from 340 +/- 43 to 817 +/- 116 microliters/min (p < 0.01); urinary sodium from 13.8 +/- 3 to 26.3 +/- 4 mumoles/min (p < 0.05). Both values returned to normal after 2-3 hrs. Taurine infusion caused a concomitant significant decrease in plasma renin activity (from 7.7 +/- 2.2 to 4.3 +/- 1.9 ng/ml/hr, p < 0.05) and aldosterone (from 588 +/- 47 to 348 +/- 89 pg/ml, p < 0.05), but no changes in atrial natriuretic peptide and arginine vasopressin. We conclude that i.v. taurine infusion in ascitic cirrhosis promotes a transient diuresis and natriuresis, apparently through the inhibition of the renin-aldosterone axis.

Adult↗

Central alpha-2 adrenergic mechanisms in the renal nerve mediated natriuresis and diuresis produced by acute volume expansion.

To determine whether central alpha-2 adrenergic mechanisms are involved in the renal nerve mediated natriuresis and diuresis produced by acute volume expansion, urine flow and sodium excretion from innervated and denervated kidneys were measured before and after acute volume expansion (1 ml/min for 20 min) in the presence or absence of intracerebroventricular yohimbine (8 micrograms/kg/min), an alpha-2-antagonist, in Inactin-anesthetized Sprague-Dawley rats. The innervated to denervated (I/D) ratio for urine flow and sodium excretion indicated that acute volume expansion caused a greater natriuresis and diuresis from the intact kidney compared to the denervated kidney. However, these I/D ratios during acute volume expansion were significantly reduced in the presence of yohimbine i.c.v. Furthermore, central administration of clonidine, an alpha-2 agonist, produces a renal nerve mediated natriuresis. These data suggest that central alpha-2 adrenergic mechanisms may be involved in producing the renal sympatho-inhibition, which subsequently produces natriuresis and diuresis, in response to acute volume expansion.

Animals↗

Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.

The renin-angiotensin-aldosterone system is activated by diuretics and involved in the diuretic resistance of cirrhotic patients with ascites and oedema. In previous studies relatively high doses of captopril (25-400 mg daily) were unsuccessful in promoting diuresis and natriuresis in these patients. We analyzed the efficacy of a low dose of captopril in eight patients with massive ascites resistant to therapy of salt/fluid restriction and increasing doses of spironolactone and furosemide. Mean duration of diuretic use was 73 days (range 7-240 days). After at least 3 days of observation on 80 mg furosemide and 100 mg spironolactone only, captopril was added. Four out of eight patients responded with an increase in natriuresis and diuresis; daily dose of captopril was 20.6 mg in responders and 26.5 mg in non-responders. After the addition of captopril the mean weight change was -7.5 kg in responders and +0.25 kg in non-responders. Mean urinary sodium output in responders increased from 72.8 (S.D. = 35.2) to 128.5 (63.5) mmol within 10 days. Increased diuresis in responders made diuretic reduction necessary: mean furosemide from 80 to 53.3 mg, and mean spironolactone from 100 to 68.1 mg. Creatinine clearances remained stable. High levels of plasma renin activity, plasma aldosterone and angiotensin-II were found in all patients. Non-responders showed more severe hyponatremia and higher vasopressin levels. Natriuretic atrial factor (NAF) was in the upper-normal range or slightly elevated in both groups. In non-responders we noticed low levels of cGMP in 24-h urine, compared with responders.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Influence of streptozotocin (STZ)-induced diabetes, dextrose diuresis and acetone on cisplatin nephrotoxicity in Fischer 344 (F344) rats.

The following studies examined the impact of the diabetic state on cisplatin nephrotoxicity. This study also investigated the potential mechanisms for diabetes mediated reduction of cisplatin toxicity. A diabetic state was induced in male Fischer 344 (F344) rats after intraperitoneal (i.p.) injection of 27-35 mg/kg STZ. Cisplatin (5 mg/kg, i.p.) nephrotoxicity was examined in normoglycemic and diabetic rats after 48 and 96 h. Cisplatin was nephrotoxic within 96 h to normoglycemic animals as indicated by an increased kidney weight, marked elevations in serum BUN levels as well as significant P less than 0.05) decreases in renal cortical slice accumulation of p-aminohippurate (PAH) and tetraethylammonium (TEA). Cisplatin failed to depress renal cortical slice accumulation of PAH and TEA in the diabetic rats. Cisplatin was also less effective in increasing BUN levels or kidney weight in diabetic rats. Further studies investigated the impact of glycosuric diuresis and ketone bodies on cisplatin nephrotoxicity. Dextrose diuresis of normoglycemic rats failed to reduce the effect of cisplatin on BUN levels, kidney weight and renal cortical slice uptake of PAH and TEA. Acetone pretreatment of normoglycemic rats also did not reduce cisplatin nephrotoxicity. These results indicate: (1) cisplatin nephrotoxicity is attenuated in the experimental diabetic state, (2) diabetes does not reduce cisplatin nephrotoxicity through glycosuric diuresis and (3) ketone body accumulation does not modulate cisplatin nephrotoxicity.

Acetone↗

Contribution of acetone and osmotic-diuresis by streptozotocin-induced diabetes in attenuation of cephaloridine nephrotoxicity.

Previous studies have indicated that cephaloridine nephrotoxicity was reduced in streptozotocin (STZ)-induced diabetic rats. Experiments were performed to investigate if a shorter duration of diabetes would reduce cephaloridine nephrotoxicity. Studies were also conducted to examine the contribution of osmotic diuresis and ketone accumulation to the mechanism for reduced toxicity. Male Fischer 344 (F344) rats were injected with 30 mg/kg STZ or vehicle. Seven days after STZ or vehicle administration, the animals were treated (i.p.) with 1500 mg/kg cephaloridine. Increased kidney weight, blood urea nitrogen (BUN) level and decreased renal cortical slice accumulation of p-aminohippurate (PAH) and tetraethyl-ammonium (TEA) were measured in the normoglycemic group. No differences in renal function were detected between diabetic groups treated with cephaloridine or vehicle (PFC). Pretreatment of euglycemic rats with 0 or 10% dextrose in the drinking water and by oral gavage failed to prevent the renal damage produced by 1500 mg/kg cephaloridine despite glucosuria and urine output comparable to diabetic animals. However, dextrose-diuresis afforded a slight reduction in toxicity as indicated by changes in kidney weight and renal cortical slice accumulation of PAH and TEA. Pretreatment (oral) with 0 or 1.5 ml/kg acetone had no effect on cephaloridine toxicity (1000 mg/kg, i.p.). These findings suggested that attenuation of cephaloridine toxicity may be independent of the duration of diabetes. These results also indicated that glucose-mediated osmotic diuresis and acetone accumulation cannot account for reduced cephaloridine toxicity in diabetic rats.

Acetone↗

Centrally mediated effect of vanadate on diuresis and natriuresis in normal rats. Interaction with ouabain.

Prolonged infusion of vanadate (VO-3) (51 ng/microliter/hr during 15 hr), an in vitro inhibitor of Na,K-ATPase activity, into the 3rd brain ventricle (3BV) increased diuresis, sodium and potassium excretion in normal rats (p less than 0.001). Since the animals did not receive food or water during the infusion period, the effect of VO-3 was not related to hydration or volume expansion. A single injection of ouabain (a specific inhibitor of the sodium pump) 1 microliter, 50 pg/microliter, followed by a single injection of vanadate (1 microliter/51 ng/microliter) 1, 5 or 10 minutes after ouabain, prevented the diuretic and natriuretic effect of VO-3. When vanadate injections were delayed 20 or 30 minutes, diuresis reappeared. Ouabain (50 pg) decreased sodium intake induced by sodium depletion, an effect that lasted for 10 to 15 minutes after injection, a time coincident with the inhibition of the natriuretic effect of VO-3 by OUA. Then the life-span of ouabain effect on prevention of VO-3-induced diuresis as well as on inhibition of sodium intake, lasted between 10 to 15 minutes. These results provide further evidence for the powerful diuretic, natriuretic and kaliuretic effect of centrally injected vanadate. However, the finding that ouabain suppresses this effect, does not support the suggestion that the active transport system might be involved.

Animals↗

Excretion of alcohol in urine and diuresis in healthy men in relation to their age, the dose administered and the time after drinking.

Healthy male volunteers drank neat whisky in amounts corresponding to 0.51, 0.68, or 0.85 g ethanol/kg body weight in 15-25 min after an overnight (10 h) fast. Urine was collected immediately before drinking and then at 60 min intervals for 7-8 h after intake. The volumes of urine voided were measured and the concentrations of alcohol (UAC) were determined by an enzymatic method. Ethanol-induced diuresis showed large inter-subject variations. The flow of urine was maximum between 60 and 120 min post-drinking when the median rates of production were 117 ml/h (range 55-335), 113 ml/h (range 41-453) and 373 ml/h (range 215-485) for 0.51, 0.68, and 0.85 g ethanol/kg respectively. The output of urine returned to normal (30-60 ml/h) after the peak UAC had passed despite an elevated blood alcohol concentration (BAC). The average amount of alcohol excreted in urine was 0.29 g (S.D. 0.119), 0.44 g (S.D. 0.246), and 1.00 g (S.D. 0.427) after the consumption of 0.51, 0.68 and 0.85 g ethanol/kg respectively. Neither peak diuresis nor the amount of alcohol excreted depended on a subject's age between 20 and 60 years. This work shows that after drinking a moderate dose of alcohol, only 0.7-1.5% of the amount consumed is excreted unchanged in urine. Ethanol-induced diuresis is most pronounced for the first 1-2 h after drinking (rising BAC). The production of urine returns to normal during the post-absorptive state.

Adult↗

A prospective randomized trial of magnesium sulfate in severe preeclampsia: use of diuresis as a clinical parameter to determine the duration of postpartum therapy.

OBJECTIVE: The purpose of this study was to assess the use of the onset of diuresis in the determination of the duration of postpartum magnesium sulfate therapy among patients with severe preeclampsia. STUDY DESIGN: A prospective randomized trial of postpartum therapy with magnesium sulfate was conducted. The control group received 24 hours of therapy, and the study group received therapy until the onset of diuresis (urine output >100 mL/hr for 2 consecutive hours). The Student t test, chi 2 test, and Fisher's exact test were used for analysis of data; a probability value of <.05 was considered statistically significant. RESULTS: There were 50 patients in the control group and 48 patients in the study group. There was no difference in maternal demographic data, severe disease criteria, blood pressure, 24-hour postpartum urine output, or need for antihypertensive therapy. The study group had a significantly shorter duration of therapy, and no patient had eclampsia or required the re-initiation of therapy. CONCLUSION: The use of the onset of diuresis in the postpartum period as the determinant clinical parameter for the discontinuation of magnesium sulfate in patients with severe preeclampsia was associated with no untoward outcomes or need for the re-initiation of treatment.

Adult↗

On the mechanism of augmentation of electrocardiogram QRS complexes in patients with congestive heart failure responding to diuresis.

Patients with congestive heart failure (CHF) responding to diuresis reveal marked augmentation of the QRS complexes (AUG-QRS) in their electrocardiograms (ECGs). Recently, such change in the ECG has been observed in patients with anasarca (AN) of varying etiology commensurate with partial alleviation of the volume overload; similar ECG change has been noted in patients with end-stage renal failure after hemodialysis. The mechanism for the AUG-QRS in patients with CHF has been debated, and many have ascribed this ECG change to the "Brody effect," linking the AUG-QRS to reduction of intracardiac blood volumes resulting from diuresis. However, the Brody effect (a theoretical formulation not fully validated by experimentation and associated with controversy in its clinical implementation) has not provided a satisfactory explanation for the AUG-QRS in patients with CHF. In contrast, the described association between amelioration of AN in a diverse patient population and AUG-QRS suggests that this ECG change in patients with CHF is due to an increased electrical resistance of the passive body volume conductor, resulting from water loss effected by diuresis. This thesis is supported by theoretical work, animal experimentation, and clinical evidence.

Body Water↗

Continuous recording of excretory water loss from Musca domestica using a flow-through humidity meter: hormonal control of diuresis.

Water loss from adult male houseflies was continuously recorded using a flow-through humidity meter, which enabled losses to be apportioned between the sum of cuticular and respiratory transpiration, salivation and excretion. Transpiration accounted for >95% of water lost from sham-injected flies, compared with excretion (3.0%) and salivation (2.4%). In contrast, excretion accounted for 40% of water lost from flies injected with > or =3 microl of saline, whereas salivary losses were unchanged. Saline injections (1-5 microl) expanded the abdomen in the dorsal-ventral plane, and this expansion was positively correlated with the magnitude of the ensuing diuresis, suggesting the signal for diuretic hormone release originates from stretch receptors in abdominal tergal-sternal muscles. The effects of decapitation, severing the ventral nerve cord within the neck or ligaturing the neck, showed the head was needed to initiate and maintain diuresis, but was neither the source of diuretic hormone nor did it control the discharge of urine from the anus. These findings indicate the head is part of the neural-endocrine pathway between abdominal stretch receptors and sites for diuretic hormone release from the thoracic-abdominal ganglion mass. Evidence is presented for Musdo-K having a hormonal role in the control of diuresis, although other neuropeptides may also be implicated.

Animals↗

Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.

Kappa opioid receptor (KOR) agonists such as U-50488H and bremazocine are analgesics and diuretics. In monkeys, the selective KOR antagonist, nor-binaltorphimine (nor-BNI), produces a long-lasting antagonism of the antinociceptive effects of U-50488H but not those of bremazocine, suggesting that KOR-mediated antinociception may occur through two distinct KORs. The aim of this study was to characterize the antagonist effect of nor-BNI against the diuretic effects of U-50488H and bremazocine in monkeys. Urine outputs were collected over 3 h subsequent to i.m. administration of KOR agonists. Both U-50488H (0.032-1 mg/kg) and bremazocine (0.00032-0.01 mg/kg) dose-dependently increased urine output and the diuretic effect reached a plateau at higher doses. The maximum effect of either U-50488H or bremazocine was approximately 15 ml/kg/3 h of urine. Pretreatment with intracisternal nor-BNI 0.32 mg significantly blocked both U-50488H (0.18 mg/kg)- and bremazocine (0.0032 mg/kg)-induced diuresis for 20 weeks. However, the same dose of nor-BNI 0.32 mg given subcutaneously was not effective. These results demonstrate that central KOR mediate KOR agonist-induced diuresis in monkeys. More important, this study provides functional evidence for a homogenous population of KOR underlying KOR-mediated diuresis and illustrates a unique pharmacological profile of nor-BNI-induced ultra-long KOR antagonism in vivo.

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cycloh↗

Diuresis and respiratory distress syndrome: physiologic mechanisms and therapeutic implications.

Previous studies have suggested that spontaneous diuresis may be important to the recovery from respiratory distress syndrome in preterm infants. Daily quantification of fluid intake (1) and urine output (O) were recorded, and O/I and alveolar-arterial oxygen gradients (AaDO2) were determined for sequential eight-hour periods in 10 inborn premature infants with RDS. Sequential timed-urine-plasma collections were obtained during the first four days of life to evaluate the role of hormonal and vasoactive factors in the acute phase of RDS. Diuresis (O/I greater than 0.80) occurred at 25 to 32 hours, preceded any significant improvement in AaDO2 (which occurred at 57 to 64 hours), and was associated with a 6.2 +/- 1.4% decrease in body weight. Although there was no significant change in glomerular filtration rate, plasma AVP concentrations, or urinary excretion of AVP in the infants, there were significant decreases in both plasma concentrations and urinary excretion of 6-keto-PGF1 alpha (stable metabolite of prostacyclin) in sequential studies. These results suggest that changes in renal function or AVP may not be of primary importance in the diuresis associated with RDS, and that decreasing levels of prostacyclin, a prostaglandin that increases vascular permeability and lowers blood pressure, may have an important physiologic role.

6-Ketoprostaglandin F1 alpha↗

Effects of the endothelin-1 receptor antagonist tezosentan on renal blood flow and diuresis during prolonged increased intra-abdominal pressure.

BACKGROUND: It has earlier been shown that increased intra-abdominal pressure (IAP) reduces renal blood circulation and urine output both clinically and experimentally. The aim of this study was to investigate the effect of endothelin-1 inhibition by the endothelin-1 receptor antagonist tezosentan on renal blood circulation and diuresis in pigs subjected to prolonged increased intra-abdominal pressure. MATERIAL AND METHODS: The IAP in domestic pigs was maintained at 30 mmHg for 3 h. One group of 10 animals was pre-treated with the endothelin-1 receptor antagonist tezosentan, and then received continuous infusion of tezosentan throughout the experiment. Another group of 10 animals served as control. We measured renal cortex blood flow, plasma renin activity, blood concentrations of endothelin-1 and aldosterone, and diuresis. RESULTS: The administration of tezosentan to pigs with an IAP of 30 mmHg was followed by reduced arterial pressure, reduced renal cortex blood flow, and reduced diuresis. The plasma renin activity increased markedly, but neither renal vascular resistance nor blood concentration of aldosterone did change significantly. CONCLUSION: Tezosentan reduced the arterial blood pressure, which resulted in decreased renal cortex blood flow, and aggravation of the oliguria usually observed under increased IAP. The plasma renin activity increased, but this was not followed by changes in renal vascular resistance, or blood concentration of aldosterone. The results indicate that drugs, which reduce the arterial pressure, may be harmful to the kidneys under increased IAP.

Abdomen↗

Unilateral post-obstructive diuresis in the neonate.

A total of 3 neonates exhibited severe post-obstructive diuresis after relief of unilateral ureteral obstruction. Of the neonates 2 had normal kidneys contralaterally while 1 had a contralateral kidney that was dysplastic. Urinary output exceeded oral intake initially in all 3 patients necessitating intravenous supplementation for up to 10 days. Stabilization resulted from an increase in oral intake rather than a decrease in diuresis. Unilateral post-obstructive diuresis is extremely uncommon but it may occur in the neonate because of the unique features of the renal physiology encountered in this age patient.

Diuresis↗

Diuresis renography and simultaneous renal pelvic pressure in hydronephrosis.

We investigated 23 hydronephrotic kidneys in 10 male and 12 female patients (mean age 32 years) with diuresis renography and simultaneous, continuous renal pelvic pressure measurement to compare isotope washout with pelvic pressure changes. No correlation was found between these 2 parameters. Of the kidneys 14 were investigated further by a standard Whitaker pressure flow study. There was only a poor correlation between diuresis renography and the pressure flow study, and between the pelvic pressures during perfusion and forced diuresis. Impaired renal uptake fraction signifying the degree of obstructive nephropathy did not correlate with the dynamic tests. An Anderson-Hynes pyeloplasty was done in 19 patients. There was no correlation between the presence of organic stenosis or external compression and the outcome of the diagnostic tests. We concluded that the currently used diagnostic procedures for hydronephrosis generally are insufficient to discriminate between significant and nonsignificant obstruction.

Adult↗